Due to the lack of estrogen, progesterone, and HER2 receptors (Bauer et al., 2007), and the inactivation of the BRCA1 gene (Anders et al., 2016), hormonal therapy, one of the most common treatments for breast cancer (Puhalla et al., 2012; Wahba and El-Hadaad, 2015), is not available, worsening the prognosis of the disease compared to other types of breast cancers (Ismail-Khan and Bui, 2010). This evidence concerns the gene BRCA1 and breast carcinoma.